Please ensure Javascript is enabled for purposes of website accessibility

Can This News Push Ocugen Ahead of Pfizer and Moderna?

By Adria Cimino - May 5, 2021 at 6:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ocugen may be able to handle one of the biggest challenges facing vaccine makers.

A year ago, Pfizer (PFE -1.30%) and Moderna (MRNA 2.42%) were working on bringing their coronavirus vaccine candidates to market. Ocugen (OCGN -0.70%) was focusing on something completely different: gene therapy for eye diseases that cause blindness. No one expected this clinical-stage company to take part in the vaccine race.

Fast-forward to December: That's when Ocugen signed on to co-commercialize Bharat Biotech's coronavirus vaccine candidate in the U.S. Ocugen will keep 45% of any profit in the U.S. Since then, the shares have soared. And investors have watched Ocugen's every step. Right now, the latest step is a report about the vaccine candidate's performance against coronavirus variants of concern or interest. Can this help Ocugen eventually leap ahead of its bigger rivals? Let's take a closer look.

A doctor holds up a syringe and prepares to vaccinate a patient.

Image source: Getty Images.

Neutralizing variants

Ocugen said this week that Covaxin -- Bharat's candidate -- neutralized the Brazil variant, the U.K. variant, and the India "double mutant" variant in a study. Scientists at the Indian Council of Medical Research performed in vitro tests using sera from Covaxin-vaccinated individuals. This is clearly important news -- especially considering that new strains have gained ground around the world.

India is currently vaccinating with Covaxin; Bharat said it's administered the investigational product to "several million" people there. The country granted the vaccine emergency authorization earlier in the year -- even before Bharat generated phase 3 data. The latest phase 3 data show the vaccine is 78% effective after the second dose.

Where do Pfizer and Moderna stand in terms of variants? They both have demonstrated efficacy in vitro against the U.K. and South African strains. Still, they both are investigating booster shots to increase immune response and better handle new variants. As for the Indian variant, it looks like Pfizer can do the job. The CEO of Pfizer's partner BioNTech told CNBC last week he's confident the vaccine can beat the Indian variant. Moderna's CEO told The Financial Times that he's still waiting for data on the Indian variant.

It's great news that Covaxin can neutralize specific strains. But at the pace new variants of interest are emerging, a vaccine or booster must address more than one -- or the company must be able to quickly adapt a booster to address that new strain. And that's why Pfizer and Moderna remain my top choices when it comes to handling variants.

The competitors' advantage

These competitors use mRNA technology: Messenger RNA instructs the body to make a viral protein, then the body mounts an immune response. Making mRNA vaccines is known to be quick. That's because researchers don't have to produce weakened virus, as they would when making a traditional vaccine.

So, makers of mRNA vaccines likely can update their vaccines or boosters more quickly than those using more traditional technologies. Covaxin is an inactivated vaccine -- it uses dead virus to stimulate immune response.

It's unlikely Ocugen's Covaxin can knock out big players like Pfizer and Moderna. But could it carve out its own share of the market? I'm skeptical here too, and here's why: President Joe Biden's administration has purchased enough doses of vaccine for all Americans -- mainly from Pfizer and Moderna, but also from Johnson & Johnson. In fact, now the president is talking about sending extra doses to other countries. That makes it hard to imagine the U.S. ordering a large number of doses from a newcomer. And Ocugen's deal with Bharat applies to U.S. sales only, so it will depend on winning orders in the United States.

Of course, Ocugen hasn't yet secured authorization for Covaxin in the U.S. Ocugen said this week that it's preparing an Emergency Use Authorization request.

More room in the future?

If we look at a market entry farther down the road, there may be a bit more room for new players. Ocugen doesn't have to be a major player to generate revenue from Covaxin, and use it to fund the development of its gene-therapy programs.

Meanwhile, Ocugen shares have surged -- greatly surpassing the performance of Moderna and Pfizer year to date:

OCGN Chart

OCGN data by YCharts.

And any further progress toward authorization in the U.S. could push the shares even higher. Investors have regularly rewarded Ocugen with major one-day gains on Covaxin news.

But this pattern of share gains doesn't change my stance on Ocugen stock. There's still way too much uncertainty regarding the biotech company's potential to take share in a market dominated by Pfizer and Moderna. And that's why I worry about the stock's prospects over the long term.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Moderna. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.82 (-0.70%) $0.02
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.46 (-1.30%) $0.65
Moderna, Inc. Stock Quote
Moderna, Inc.
$175.32 (2.42%) $4.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.